Biohaven Ltd. (BHVN) Analyst Ratings
BHVN Analyst Consensus & Price Target
Biohaven Ltd. (BHVN) carries a consensus rating of Moderate Buy from 9 analysts on record (Sep 3, 2025 to Jun 29, 2026): 5 bullish, 3 neutral, 1 bearish. The average price target is $23.44 (range $9.00 to $75.00), with wide disagreement among analysts. That implies +52.1% upside from the current price of $15.41. Recent activity leans toward downgrades: 1 upgrade vs 5 downgrades on record. The price target on record has moved from $75.00 to $11.00 (-85.3%) between Sep 3, 2025 and Jun 29, 2026.
One vote per analyst, using each firm's most recent rating on record, not every historical reiteration counted separately.
Each analyst's most recent target on record, compared against where the stock actually trades. See how actual results have compared to estimates →
Is the average price target keeping pace with the stock, running ahead of it, or lagging behind? Compares the target's overall drift on record (across different analysts) to the stock's own move over the same window.
The stock has moved faster than analysts have updated their targets, targets may be playing catch-up.
Every rating on record, most recent first. "Next-close move" is the stock's own move from the prior close to the rating date's close, where price history lines up, a data point per event, not an averaged claim.
| Date | Analyst | Action | Rating | Price Target | Move |
|---|---|---|---|---|---|
| Jun 29, 2026 | BofA Securities | Downgrade | Neutral to Underperform | $11 | -5.56% |
| Apr 13, 2026 | Canaccord Genuity | Initiated | Buy | $21 | +10.36% |
| Feb 6, 2026 | Goldman | Initiated | Buy | $23 | +7.81% |
| Jan 21, 2026 | RBC Capital Mkts | Upgrade | Sector Perform to Outperform | $22 | +1.50% |
| Dec 3, 2025 | H.C. Wainwright | Downgrade | Buy to Neutral | $11 | +3.28% |
| Nov 26, 2025 | UBS | Downgrade | Buy to Neutral | $11 | +0.74% |
| Nov 6, 2025 | Bernstein | Downgrade | Outperform to Mkt Perform | $9 | +2.28% |
| Nov 5, 2025 | BofA Securities | Downgrade | Buy to Neutral | $10 | -40.22% |
| Sep 17, 2025 | Citigroup | Initiated | Buy | $28 | +8.97% |
| Sep 3, 2025 | Raymond James | Initiated | Strong Buy | $75 | +2.01% |
What is the analyst consensus rating for BHVN?
Biohaven Ltd.'s consensus rating is Moderate Buy, based on 9 analysts' most recent ratings on record: 5 bullish, 3 neutral, 1 bearish.
What is BHVN's average analyst price target?
The average price target on record is $23.44, ranging from $9.00 to $75.00 across 9 analysts, wide disagreement. That implies +52.1% from the current price of $15.41.
Are analysts upgrading or downgrading BHVN right now?
On record between Sep 3, 2025 and Jun 29, 2026: 1 upgrade, 5 downgrades, 4 new initiations, and 0 reiterations.
Are analyst price targets for BHVN rising or falling?
The price target on record moved from $75.00 on Sep 3, 2025 to $11.00 on Jun 29, 2026, a change of -85.3%. This compares different analysts over time, not one analyst's revision.
How many analysts cover BHVN?
9 analysts have rated BHVN in the data on record, spanning Sep 3, 2025 to Jun 29, 2026.